PHAT

4.6608.27%
MF

Michael F. Cola

Independent chairman of the Board

Mr. Michael F. Cola, also known as Mike, was Chief Executive Officer of Cybin Inc. from February 10, 2026 until April 20, 2026. Mr. Cola is an Independent Chairman of the Board of Phathom Pharmaceuticals, Inc. He served as Chief Executive Officer at Avalo Therapeutics, Inc. (formerly Cerecor Inc.) since February 3, 2020 until February 14, 2022 and served as its Principal Executive Officer and served as its Director at since February 3, 2020 until February 16, 2022. He served as Chairman at Avalo Therapeutics, Inc. since 2021 until December 14, 2021. He is Chief Executive Officer of Helus Pharma. Mr. Cola served as Interim Chairman at Avalo Therapeutics, Inc. since August 2021 until 2021 & served as its President since February 3, 2020 until August 2021. Mr. Cola served as Chairman at Avalo Therapeutics, Inc. (formerly Cerecor Inc.) since June 15, 2021 until August 2021. Mr. Cola had been the Chief Executive Officer, President and Director of Aevi Genomic Medicine, Inc. since September 13, 2013 until February 3, 2020. Mr. Cola is an Independent Director of Phathom Pharmaceuticals, Inc. since September 2019 and served as its Interim Chairman since February 2022. He served as an Executive Officer at Shire plc since April 2, 2012. Mr. Cola served as the President of Specialty Pharmaceuticals at Shire Limited from 2005 until April 2012. Mr. Cola served as an Executive Vice President for Global Therapeutic Area Business Units at Shire Limited since July 2005. He was responsible for leading Shire's therapeutic teams. He joined Shire in 2005 as Executive Vice President of Global Therapeutic Business Units and Portfolio Management. He served as the Managing Director of Corporate Operations for Safeguard Scientifics Inc. a holding company of Laureate Pharma, Inc. since January 2002 and served as Group President of Life Sciences from 2000 to June 2005. He joined Safeguard in February 2000 as its Vice President of operations and management services. He served as a Managing Director of HealthCare and Life Sciences of Safeguard Scientifics, Inc. He served at Astra Merck/AstraZeneca Plc, where he served as a Vice President of Global Clinical Operations and responsible for global clinical & U.S. product development operations & technology solutions integration, product development, medical affairs, business research, licensing and pharmaceutical business units. He worked at the Campbell Soup Company in manufacturing and product development. Mr. Cola served as the Chief Executive Officer of Clarient Inc. and served as its Interim Chief Executive Officer from February 2004 to July 2004. Mr. Cola also served on the Life Sciences Pennsylvania Board (formerly named Pennsylvania Bio) from 2009 until 2015. He has drug development and research & development. He spent years in clinical and pre-clinical research at the University of Pennsylvania. He served as Chairman of NuPathe Inc. since December 2006 and has been its Director since January 16, 2007. Mr. Cola served as the Chairman of Clarient Inc. since June 16, 2003 and its Director since July 2000. He served as Chairman of Laureate Pharma. He had been an Independent Director of Vanda Pharmaceuticals, Inc., since June 2012 until February 14, 2020. He served as Member of Scientific & Strategic Advisory Board at Delix Therapeutics, Inc. since June 2021 until April 2026. He was an Independent Director at Sage Therapeutics, Inc. since September 2014 until July 31, 2025. Mr. Cola joined the Sage Therapeutics, Inc. in September 2014. He served as a Director of Ventaira Pharmaceuticals Inc. He serves as the Chairman of the Board of Governors of the Boys & Girls Clubs of Philadelphia. He serves as a Director of The Pennsylvania Biotechnology Association. He served as a Director of Sotas, Inc. and Mi8 Corporation. He served as a Director of Mantas, Inc. Mr. Cola holds a BA Degree in Biology and Physics from Ursinus College, an M.S. in Biomedical Science and Engineering from Drexel University and studied Bioengineering at the University of Pennsylvania, where he also worked as a biomedical engineer at its affiliated hospital.

Positions